Japanese companies Ono Pharmaceutical and Meiji Seika have announced an agreement on the development and commercialization of Limparost alfadex, for lumbar spinal canal stenosis. 29 July 2014
Anglo-Swedish drug major AstraZeneca has said it is collaborating with Netherlands company Qiagen and Swiss drug major Roche to develop blood tests analyzing the DNA from a patient’s tumor circulating in the blood to determine the epidermal growth factor receptor (EGFR) mutation status of their tumor. 28 July 2014
The European Medicines Agency's Committee for Medicinal Products for Human Use, at its July meeting, backed the granting marketing authorizations for two new drugs with novel mechanisms of action for the treatment of different forms of rare cancers of the blood. 26 July 2014
At its July 2014 meeting, the European Medicines Agency’s Committee for Medicinal Products for Human Use issued positive opinions for the recommendation of a number of new drugs, including the following: 26 July 2014
The European Society for Medical Oncology (ESMO) has expressed concern that the proposed European Union General Data Protection Regulation could make cancer research impossible and add a significant burden to cancer patients and doctors. 25 July 2014
Japanese oncology-focussed drugmaker Taiho Pharmaceutical has said that it will be investing $30 million in Remiges BioPharma Fund, a newly formed biotech venture capital fund created by Remiges Ventures. 25 July 2014
German drug major Bayer and Onyx Pharmaceuticals, an Amgen subsidiary (Nasdaq: AMGN), have said that an investigational Phase III trial of Nexavar (sorafenib) tablets in patients with advanced breast cancer did not meet its primary endpoint of improving progression-free survival. 25 July 2014
The US Food and Drug Administration has accepted the Biologics License Application for filgrastim, which was filed under the new biosimilar pathway created in the Biologics Price Competition and Innovation Act of 2009 (BPCIA), by Sandoz, the generics business of Swiss pharma major Novartis. 25 July 2014
US pharma major Bristol-Myers Squibb and Japan’s Ono Pharmaceutical have signed a strategic collaboration to jointly develop and commercialize multiple immunotherapies as single agents and combination regimens to help address the unmet medical needs of patients with cancer in Japan, South Korea and Taiwan. 24 July 2014
Swiss pharma major Roche, the world’s leading oncology company, this morning posted first-half 2014 financial results, showing that the strength of the Swiss franc against other currencies had a negative impact, despite rising sales of its new cancer drugs. 24 July 2014
The US Food and Drug Administration late yesterday approved Zydelig (idelalisib), a new drug from US biotech major Gilead Sciences to treat patients with three types of blood cancers. 24 July 2014
US development-stage company Puma Biotechnology saw its share more than triple to $190 in after-hours trading yesterday, when the released positive research results with its investigational breast cancer drug neratinib. 23 July 2014
The increased use of targeted therapies, along with a greater uptake of branded drugs and rising incidence population, will cause the breast cancer therapeutics market value to grow from $9.2 billion in 2013 to $13.1 billion by 2020. 23 July 2014
The UK’s National Institute for Health and Care Excellence (NICE) has issued guidance recommending new prostate cancer drug Xtandi (enzalutamide) and extending the use of Yervoy (ipilimumab) for skin cancer for use on the Natiional Health Service. 23 July 2014
PharmaMar, biopharmaceutical company which represents the main affiliate of Spanish Grupo Zeltia is diversifying its business model with the intention, according to official statements, “of financing the development of its pipeline of biological products coming from the sea to treat several types of cancer.” 22 July 2014
US-based pharmaceutical company Halozyme Therapeutics has said it is once again enrolling and dosing patients in its ongoing Phase II trial to evaluate PEGPH20 in patients with pancreatic cancer under the revised clinical protocol agreed with the US Food and Drug Administration last month. 22 July 2014
Anglo-Swedish drug major AstraZeneca says that its global biologics research and development arm MedImmune has entered into a clinical trial collaboration with Advaxis, a USA-based biotechnology company developing cancer immunotherapies. 22 July 2014
Australian biotech company Regeneus has expanded its portfolio to include licensing of global rights to an autologous human cancer vaccine. 22 July 2014
In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Pfizer released positive top line results from the final prespecified overall survival (OS) analysis of the TALAPRO-2 study of Talzenna (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with Xtandi (enzalutamide). 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
Cancer start-up Black Diamond Therapeutics has announced a significant restructuring as part of its plan to focus resources on its lead drug, BDTX-1535. 10 October 2024
The European Medicines Agency (EMA) has accepted for review the Marketing Authorization Applications for AVT03, a proposed biosimilar candidate to the Prolia and Xgeva (denosumab), submitted by Germany’s STADA Arzneimittel. 10 October 2024
China’s Quantum Pharmaceuticals has announced a significant licensing agreement between its biologics-focused subsidiary, Ailux Biologics, and Johnson & Johnson. 10 October 2024
Advances in gene editing, such as the FDA approval of Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) in December 2023 for the treatment of beta thalassemia and sickle cell disease, have fueled significant interest in innovative epigenetic drugs. 10 October 2024
German family-owned pharma major Boehringer Ingelheim and USA-based Circle Pharma (have entered into a research collaboration and license agreement with the shared goal to develop a first-in-class cyclin inhibitor that can halt the growth of cancer cells potentially offering hope to those living with hard-to-treat cancers. 9 October 2024
Bayer has entered into a collaboration with MOMA Therapeutics to develop a small molecule oncology program using the latter’s proprietary KNOMATIC platform. 9 October 2024
Genor Biopharma has announced plans for a significant merger with Edding Group, marking one of the first reverse takeovers involving a Hong Kong-listed biopharma company. 8 October 2024
China-headquartered clinical-stage biotech MediLink Therapeutics has announced a global clinical trial collaboration and supply agreement with US major Amgen. 8 October 2024
Germany’s Eckert & Ziegler, a specialist in radioisotopes for medical, scientific and industrial applications, has announced a global clinical supply agreement with GlyTherix, an Australian targeted radiotherapy firm specializing in developing antibody radiopharmaceuticals for solid tumors. 8 October 2024
US clinical-stage biotech OnKure Therapeutics has announced the completion of its previously announced merger with Reneo Pharmaceuticals. 8 October 2024
Daejeon-based Orum Therapeutics, a specialist in degrader-antibody conjugates (DAC), has filed for an initial public offering (IPO) on South Korea's Kosdaq market. 7 October 2024
Mosaic Therapeutics, a UK-based oncology therapeutics company dedicated to resolving cancer’s complexity to power new combination therapies for patients, has announced the appointment of Barry Davies as chief scientific officer. 7 October 2024